Haleon Believes It Is Not Liable for Any Potential Zantac Liabilities
LONDON (Reuters) – Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company’s CEO Brian McNamara told Reuters on Tuesday. More than 2,000 legal cases related to Zantac have been filed in the United States over allegations that the compound contains a probable carcinogen. Zantac, originally marketed […]
Continue reading »